Pathological Results of Aggressive Hepatocellular Carcinomas Treated Using SIRT

The aim of our study is to analyze pathological analysis of surgically treated aggressive hepatocellular carcinomas after radio-embolization.

The investigators aim to demonstrate that a higher dose results in better tumor response while respecting safety conditions, that is, no radiologically induced liver disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Uhmontpellier

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

aggressive hepatocellular carcinomas with vascular invasion, large tumors or multifocal distribution

Exclusion criteria

Other treatment after SIRT (confounding effect)
contraindications for surgery

Treatment and study plan

Primary outcomes

Pathological tumor response

Time frame: 6 months

Patients are treated with SIRT, then if the tumor response was adequate, surgery was performed.Analysis after surgery. (6 months after SIRT)

Secondary outcomes

Rate of Healthy liver hypertrophia

Time frame: day 1

Rate of Healthy liver hypertrophia

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Pathological Results After Downstaging of Agressive Hepatocellular Carcinoma Using 90Y-SIRT With Personalized Dosimetry

Acronym: PAHCHS

Important dates

Study start: 2014
Primary completion: 2021
Study completion: 2021
First posted: Sep 16, 2021
Registry last updated: Oct 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed